Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

BODYBUILDERS’ SUPPLEMENT STALLS AGING

BODYBUILDERS’ SUPPLEMENT STALLS AGING
Alpha-ketoglutarate (AKG), a supplement bodybuilders use to bulk up, has delayed the symptoms of aging and extended healthspans in mice, researchers at California’s Buck Institute for Research on Aging have found.
AKG occurs naturally in mammals, including humans, and is a compound needed to convert food into energy. Physicians sometimes prescribe it to treat kidney disease and osteoporosis.
The researchers began feeding black-furred mice 2 percent of their daily food allotment as AKG, starting when the mice were 18 months old, equivalent to age 55 in humans.
Soon, the treated mice looked “blacker, shinier, and younger” than their untreated litter mates.
The treated mice also scored an average of more than 40 percent better than their untreated siblings on 31 tests of “frailty,” including hearing, gait, and grip strength. Female mice receiving AKG lived 8 to 20 percent longer, probably because AKG blocks inflammation, a key cause of several diseases associated with aging, the researchers said.
The youthful mice performed no better on tests of heart function or treadmill endurance. Mental acuity was not tested.
AKG had less effect on mice’s health and lifespan than other compounds, such as rapamycin, a drug used to suppress organ rejection after transplants. But, in addition to suppressing the immune system, rapamycin can promote diabetes.
“The big thing about [AKG] is that its safety profile is so good,” said Holly Brown-Borg, a leading researcher on aging at the University of North Dakota. She was not involved in the Buck project.
Two human trials are now under way using middle-aged to older adults to determine AKG’s effects on such aging markers as inflammation, hardening of arteries, and changes to DNA.
TRENDPOST: Medical research, especially in aging, is shifting from the search for new,  more powerful synthetic drugs to enhancing or amplifying the body’s own health-maintaining compounds and processes.
 

Comments are closed.